AZACITIDINE COMBINED TO EPOETIN BETA IN INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS) LOW-RISK AND INTERMEDIATE-1 MYELODYSPLASTIC SYNDROME (MDS) PATIENTS, RESISTANT TO ERYTHROPOETIN-STIMULATING AGENTS (ESA):